Accessibility Menu

Biolase(OTC) BIOLQ

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-100%
5 YearN/A
1 Year-100%
1 Month+0%
$0.00
+0.00%
+0.00Today
Biolase last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-17
Biolase stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-10
1 month+0%USD 0.002026-06-16
3 month-99%USD 0.002026-04-17
Year to date+0%USD 0.002025-12-31
1 year-99.99%USD 0.012025-07-17
Since inception-100%USD 199,459.831992-11-12

Biolase Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$10.85

Net Income (TTM)

-$1.43

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-76.93 (Low)

Price

$0.00

Volume

17

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

N/A

BIOLQ News

The Fool Looks Ahead

Rick MunarrizNov 9, 2013

Up 25%, the Anti-Dentite's Nightmare Stock Surges

Brenton FlynnFeb 6, 2013

Whoa! What Just Happened to My Stock?

Rich DupreyAug 11, 2011

The Stocks Wall Street Loves

Rich DupreyJul 28, 2011

How to Ride This Crazy Roller-Coaster

Anders BylundJun 26, 2011

3 Stocks Shaking the Market

Rich DupreyApr 7, 2011

Tuesday's Worst Stocks in the World

Tim BeyersNov 7, 2007

Wall Street's Buy List

Rich SmithOct 23, 2007
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biolase

BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Lake Forest, CA.

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

157

CEO

John R. Beaver, CPA

Website

www.biolase.com

BIOLQ Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

36.60M

Volume

17

Avg. Volume

206

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Biolase Performance Analysis

Biolase annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 39,188,000N/A
20222022-12-31USD 48,462,00023.7%
20232023-12-31USD 49,164,0001.4%
Biolase annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -282.65N/A
20222022-12-31USD -416.3247.3%
20232023-12-31USD -29.44-92.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$10.85

N/A

Gross Profit

$4.38

N/A

Gross Margin

40.39%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

-$1.43

N/A

EBITDA

-$0.05

N/A

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$20.90

N/A

Total Debt

$17.46

N/A

Accounts Receivable

$3.53

N/A

Inventory

$9.87

N/A

Long Term Debt

$0.56

N/A

Short Term Debt

$16.90

N/A

Return on Assets

-48.61%

N/A

Return on Invested Capital

-160.44%

N/A

Free Cash Flow

-$4.51

N/A

Operating Cash Flow

-$4.47

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,489.72+0.01%
^DJIDJI
$52,485.03+0.01%
^IXICNASDAQ
$25,373.85+0.01%
BTCBitcoin
$62,504.00-0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About BIOLQ

What is the current price of Biolase?

Biolase is trading at $0.00 per share.

What is the 52-week range for Biolase?

Over the past 52 weeks, Biolase has traded between $0.00 and $0.01.

How much debt does Biolase have?

As of the most recent reporting period, Biolase reported total debt of $17.46M.

How much cash does Biolase have on hand?

Biolase reported $3.44M in cash and cash equivalents in its most recent financial results.

What is Biolase’s dividend yield?

Biolase does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services